MedTrace Logo

Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis

NCT05246267 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-01-22

No results posted yet for this study

Summary

The central hypothesis of this study is that the addition of dupilumab treatment onto standard-of-care intranasal corticosteroids will improve patient-reported measures of disease activity and sense of smell in a cohort of mostly ethnical and racial minority patients with CRSwNP

Conditions

Interventions

BIOLOGICAL

Dupilumab

Standard of care treatment with dupilumab

Sponsors & Collaborators

Principal Investigators

  • Golda Hudes, MD · Montefiore Medical Center

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-15
Primary Completion
2026-06-30
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05246267 on ClinicalTrials.gov